ADVANCED HEART FAILURE RESEARCH
The Advanced Heart Failure Research (AHFR) program conducts clinical, engineering and scientific research and development (R&D) to clinically translate novel diagnostic tools and innovative therapies for advanced heart failure (HF). We also provide extraordinary educational opportunities for medical, engineering, and perfusion students that offers ‘hands on’ practical experience in a fast-paced, real world environment interacting with engineers, clinicians, scientists, and industry partners. Our broad research focus is to understand physiologic responses and remodeling of the heart, vasculature, blood, and end-organs during mechanical circulatory support (MCS) for the treatment of advanced HF to improve HF patient outcomes and restore quality of life. Our specific research foci are to develop MCS HF therapies that promote myocardial recovery; develop control strategies that enable rotary pumps to predict and respond physiologically; and elucidate mechanisms of cardiovascular remodeling. We have co-authored over 200 journal articles and received over $40 million funding from the National Institutes of Health Heart, Lung, and Blood Institute (NIH-HLBI) Research Project (R01) and Small Business Innovation Research (SBIR), Kentucky Science and Technology Corporation (KSTC), American Heart Association (AHA), Whitaker Foundation, and industry sponsors that supported research and development of novel bioinstrumentation, data acquisition and analysis systems; and MCS device testing to demonstrate efficacy and safety in compliance with Good Laboratory Practices (GLP). We are also actively engaged with the MCS field through dissemination of discovery and new knowledge and our service to international organizations, including the American Society Artificial and Internal Organs (ASAIO), International Society Rotary Blood Pumps (ISRBP), International Society of Heart and Lung Transplantation (ISHLT), and Gordon Research Conference (GRC) on Assisted Circulation. Our efforts with pre-clinical testing (CII) and clinical trials (Jewish Hospital) have led to successful CE Mark and/or FDA approval of many MCS devices in clinical use today.